sialyltransferase activity, while IgG from these patients showed corresponding changes in its glycosylation profile, as well as increased inflammatory activity, which suggests that related pathways might contribute to the onset and progression of autoantibody-mediated diseases in humans.
RESULTS

IL-23 determines the onset but not the effector phase of arthritis
In an effort to elucidate the specific role of IL-23 during the pathogenesis of RA, we sought to delineate its contributions to various phases of autoimmune-driven arthritis. Therefore, we used mice deficient in the IL-23-specific subunit p19 (Il23a −/− mice) or, alternatively, applied an antibody directed against mouse IL-23p19 to neutralize IL-23 in vivo, and studied the models of collagen-induced arthritis (CIA) 7 and K/BxN arthritis 2, 6 . During CIA, mice form arthritogenic autoantibodies to type II collagen (CII) in response to active immunization with CII, whereas K/BxN mice spontaneously develop arthritogenic autoantibodies to glucose-6-phosphate isomerase (GPI). Both models are characterized by an initial break in self-tolerance, the appearance of arthritogenic autoantibodies and the subsequent development of autoantibody-induced joint inflammation and thus reflect the key immunological and clinical features of human RA 1 , to which CII and GPI have been likewise linked as potential autoantigens 19 . By studying the clinical course of CIA and K/BxN arthritis, as well as that of the arthritis that develops after passive transfer of the corresponding autoantibodies, we aimed to determine the individual roles of IL-23 during the initiation and subsequent autoantibody-mediated effector phase of arthritis. CIA developed in wild-type mice but not in Il23a −/− mice (Fig. 1a) . Neutralization of IL-23 with the IL-23p19-neutralizing antibody (continuous application of 5 mg antibody per kg body weight from day 14 after birth, twice a week, unless specified otherwise) resulted in substantial suppression of the spontaneous arthritis in K/BxN mice, whereas treatment with an IgG isotype-matched control antibody did not interfere with development of disease in these mice (Fig. 1b) . However, we did not detect any difference in arthritis severity after we injected CII-specific antibodies into wild-type mice and Il23a −/− mice (Fig. 1c) . Also, passive transfer of serum from arthritic K/BxN mice induced arthritis of equal severity in wild-type mice and Il23a −/− mice, as well as in wild-type mice that received continuous injections of the IL-23p19-neutralizing antibody or the corresponding IgG isotype-matched control antibody ( Fig. 1d and Supplementary  Fig. 1 ). These data suggested that IL-23-dependent mechanisms were essential for the induction of an arthritogenic autoantibody response during CIA and in K/BxN mice but did not contribute to the autoantibody-mediated inflammatory effector phase of arthritis that subsequently developed.
IL-23 defines the inflammatory activity of autoantibodies
To understand the effect of IL-23 on the humoral autoimmune response during CIA and K/BxN arthritis in more detail, we measured the corresponding arthritogenic autoantibodies to CII and GPI in serum. Despite the finding that they were protected from CIA, Il23a −/− mice developed titers of CII-specific IgG similar to those of their arthritic wild-type littermates ( Fig. 2a and Supplementary  Fig. 2a-c) . Similarly, GPI-specific antibody titers in K/BxN mice that had received the IL-23p19-neutralizing antibody did not differ from the titers in those that received the corresponding IgG isotype-matched control antibody (Fig. 2b) . These findings indicated a disconnection between the development of humoral autoimmunity and the onset of arthritis in the absence of IL-23. Notably, CII-specific autoantibodies in Il23a −/− mice and their wild-type littermates did not differ in isotype composition, epitope specificity or affinity, as determined by ELISA, murine CII-epitope bead array and potassium-thiocyanate-titration assay, respectively ( Supplementary  Fig. 2b-e) . Immunofluorescence microscopy and flow cytometry revealed that wild-type mice and Il23a −/− mice also had a similar number of germinal centers and germinal-center B cells during CIA ( Supplementary Fig. 2f,g ) and generated similar titers of high-affinity antibodies to other model antigens, such as 4-hydroxy-3-nitrophenylacetyl (Supplementary Fig. 2h) , suggestive of normal affinity maturation in the absence of IL-23.
Next we assessed the effect of IL-23 on the inflammatory activity of distinct immunoglobulin fractions after the onset of arthritis. At 50 d after induction of CIA, protein-G-purified IgG from the serum of wild-type and Il23a −/− mice was used to generate either nonspecific immunocomplexes (ICs) or CII-specific ICs. To test the inflammatory potential of these different classes of ICs, we incubated them with bone-marrow-derived dendritic cells (BMDCs) from wild-type mice and performed ELISA-based measurement of the IC-induced concentrations of the pro-inflammatory cytokines IL-6, TNF and CXCL1 in the BMDC supernatants. Incubation of BMDCs with monomeric IgG or nonspecific ICs from either wild-type mice or Il23a −/− mice induced negligible amounts of these inflammatory cytokines (Fig. 2c) . In contrast, incubation of BMDCs with CII-specific ICs isolated from wild-type mice triggered robust production of these inflammatory mediators (Fig. 2c) . Notably, this potential of CII-specific ICs to induce cytokines was present mainly in IgG isolated from the serum of wild-type mice, whereas CII-specific ICs isolated from the serum of Il23a −/− mice displayed diminished inflammatory activity and induced significantly lower concentrations of cytokines in BMDCs (Fig. 2c) . These data indicated that the inflammatory properties of CII-specific ICs were IL-23 dependent. We consequently determined the contribution of IL-23 to the inflammatory activity of K/BxN serum and investigated whether blockade of IL-23 in K/BxN mice would alter the capacity of their serum to induce serum-transfer arthritis. Serum from K/BxN mice treated with the IL-23p19-neutralizing antibody (collected weekly at weeks 6-12) showed much lower potential to induce arthritis in wild-type mice than did serum from K/BxN mice treated with IgG isotypematched control antibody, although the neutralization of IL-23 had no effect on the titers of GPI-specific autoantibodies in these mice (Fig. 2b,d ). Together these data showed that IL-23 acted as a decisive factor during the generation of the inflammatory and arthritogenic autoantibody repertoire.
IL-23 unlocks autoantibody activity via IgG glycosylation
To determine the molecular correlate for the IL-23-dependent increase in the pro-inflammatory activity of autoantibodies, we performed mass spectrometry of purified total IgG, nonspecific IgG that had been depleted of CII-specific IgG, and CII-specific IgG from wild-type and Il23a −/− mice on day 50 after the induction of CIA. CII-specific IgG from wild-type mice had a lower sialic acid content at Asn297 within the Fc region of the immunoglobulin heavy chain than that of nonspecific IgG (Fig. 3a and Supplementary Fig. 3 ). Such diminished IgG sialylation, however, was not present in the CII-specific antibodies of Il23a −/− mice ( Fig. 3a and Supplementary Fig. 3) , indicative of an IL-23-mediated decrease in the sialylation of CII-specific antibodies during onset of CIA. The content of galactose or fucose at Asn297 did not differ among the groups of IgG analyzed (Fig. 3a) . Terminal sialic acid residues of Asn297 have been linked to the regulation of IgG conformation and interfere with the pro-inflammatory potential of IgG 20 , which suggests that the IL-23-mediated increase in the inflammatory 1 0 6 VOLUME 18 NUMBER 1 JANUARY 2017 nature immunology A r t i c l e s activity of CII-specific IgG was potentially linked to the diminished sialylation of Asn297 in CII-specific IgG.
To address that hypothesis experimentally, we isolated IgG from the serum of wild-type mice and Il23a −/− mice on day 50 after the induction of CIA and removed the terminal sialic acid at Asn297 in IgG by neuraminidase-mediated digestion or, alternatively, added additional sialic acid by incubating IgG from wild-type mice with recombinant sialyltransferase. We determined the inflammatory activity of the CII-specific ICs generated from these enzymatically modified IgG fractions by measuring the secretion of IL-6, TNF and CXCL1 from wild-type BMDCs incubated with these ICs. Neuraminidase-mediated removal of sialic acid did not affect the cytokine secretion induced by CII-specific ICs from wild-type mice relative to that induced by unmodified CII-specific ICs, but such removal substantially increased the cytokine secretion triggered by CII-specific ICs from Il23a −/− mice relative to that induced by unmodified CII-specific ICs (Fig. 3b) . The sialyltransferase-mediated addition of sialic acid to the IgG of wild-type mice, on the other hand, resulted in diminished inflammatory activity of the resulting CII-specific ICs, as they showed lower potential to induce cytokine secretion by BMDCs than did unmodified CII-specific ICs (Fig. 3c) . These data showed that the diminished inflammatory activity of CII-specific antibodies from Il23a −/− mice could be attributed to the increased sialylation of this IgG fraction.
Next we isolated IgG from the serum of K/BxN mice treated with the IL-23p19-neutralizing antibody or the corresponding IgG isotype-matched antibody, as a control. The neutralization of IL-23 in K/BxN mice abolished the ability of their IgG to induce arthritis when transferred into wild-type control mice (Fig. 3d) . However, neuraminidase-mediated removal of sialic acid in IgG isolated from K/BxN mice treated with the IL-23p19-neutralizing antibody restored the ability of this IgG to induce arthritis to a degree similar to that of IgG from K/BxN mice treated with IgG isotype-matched control antibody (Fig. 3c) . These data indicated that IL-23 was required for a decrease in the sialylation of arthritogenic IgG antibodies that directly resulted in an increase in its inflammatory activity and the onset of arthritis.
IL-23 regulates sialyltransferase expression in plasma cells
The enzyme β-galactoside α2,6-sialyltransferase 1 (St6gal1) acts as the rate-limiting enzyme during the post-translational transfer of sialic acid to the IgG-linked N-glycans in antibody-producing cells 21 . To delineate the mechanisms underlying the IL-23-mediated control of autoantibody glycosylation, we analyzed the expression of St6gal1 mRNA and St6gal1 protein in plasmablasts and plasma cells from the spleen and bone marrow of wild-type and Il23a −/− mice before and at various time points after the induction of CIA. Whereas we detected no difference between genotypes in St6gal1 expression before the induction of CIA (day 0), the expression of both St6gal1 mRNA and St6gal1 protein decreased during the prodromal phase of CIA (day 26) in antibodyproducing cells in wild-type mice but not in Il23a −/− mice (Fig. 4a-c and Supplementary Fig. 4a,b) ; this suggested that IL-23 directly or indirectly suppressed the expression of St6gal1 in developing plasma cells before the onset of CIA. In addition, we immunized wild-type and Il23a −/− mice with ovalbumin (OVA) in the presence of complete Freund's adjuvant and used fluorescein-isothiocyanatelabeled OVA to track individual and newly generated OVA-specific plasma cells in the immunized mice. Flow cytometry showed significantly higher expression of St6gal1 in Il23 −/− OVA-specific B220 lo CD138 + CD267 + plasma cells than in their wild-type counterparts (Fig. 4d) . Together these results indicated that IL-23 promoted the downregulation of St6gal1 expression in newly formed antibody-producing cells during the prodromal phase of arthritis and in response to antigen-specific immunization.
T H 17 cells suppress St6gal1 expression in plasma cells
To explore the mechanisms underlying the IL-23-mediated suppression of St6gal1 in plasma cells, we next characterized in more detail the IL-23-dependent T H 17 response in secondary lymphatic organs and joints during CIA in wild-type mice. Flow cytometry showed that IL-17-expressing CD3 + T cells were present in spleen and lymph nodes at steady state and during the onset of arthritis (from day 0 to day 42 after the induction of CIA) ( Supplementary Fig. 5a-c) . Starting from day 5 after the induction of CIA, we additionally detected a population of IL-17 + CD3 + CD4 + T cells in the spleen that co-expressed IL-17 and IL-22 and that was absent at steady state ( Supplementary  Fig. 5d ). In contrast, IL-17A-expressing CD3 + T cells were almost undetectable in the joints of healthy mice or in mice before and after onset of arthritis (at day 0 and days 26 and 42 after the induction of CIA) ( Supplementary Fig. 5a-c ) . Immunofluorescence microscopy showed that the IL-17 + and RORγt + CD3 + T cells that appeared in the spleen resided in clusters of IgD − B220 + CD21-CD35 + follicular B cells that expressed the transcriptional repressor Bcl-6 (Fig. 5a,b and Supplementary Fig. 5e ), which identified these structures as newly formed germinal centers. Immunofluorescence microscopy and flow cytometry additionally revealed that the IL-17 + and RORγt + T cells displayed markers of follicular helper T cells, such as Bcl-6 and PD-1 (Fig. 5a,b and Supplementary Fig. 5e ). In accordance with the proposal of a key role for IL-23 in the maintenance and induction of a pathogenic T H 17 response during the prodromal phase of arthritis, we observed significantly fewer RORγt + PD-1 + T H 17 cells in the spleen of Il23a −/− mice than in that of wild-type mice, at day 26 after induction of CIA (Fig. 5b) .
Next we sought to identify potential T H 17 cell-derived signals that might regulate St6gal1 expression in developing plasma cells. of IL-17A and IL-17F or of the cytokine GM-CSF did not (Fig. 5d) ; this demonstrated that IL-23-activated T H 17 cells were able to suppress St6gal1 expression in an IL-21-and IL-22-dependent manner (Supplementary Fig. 5f ). We did not detect expression of the IL-22 receptor on naive splenic B cells from wild-type mice; however, we observed an upregulation of the expression of mRNA and protein for this receptor in B cells in which we had initiated plasma cell differentiation by the addition of LPS, as well as in splenic B cells at day 26 after the induction of CIA (Supplementary Fig. 5g-i) . These data suggested that B cells gained the ability to respond to T cell-derived IL-22 during plasma cell differentiation and during the prodromal stage of autoimmune arthritis.
Diminished IgG sialylation parallels the clinical onset of RA To determine if changes related to those noted above parallel the onset of clinical disease in human RA, we next sought to analyze the activity of sialyltransferases in antibody-producing cells of patients with RA and healthy control subjects. As a 'readout' for sialyltransferase activity, we used fluorescein-isothiocyanate-labeled Sambucus nigra (SNA) lectin to measured sialic acid on the surface of CD27 hi CD38 hi CD19 + plasmablasts in the peripheral blood of healthy control subjects and ACPA + patients with RA. Control experiments showed that wild-type B cells, but not those from St6gal1-deficient mice, stained positively for SNA lectin (Supplementary Fig. 6a-c) , which confirmed the hypothesis that the extent of SNA binding could serve as a suitable surrogate marker for sialyltransferase activity in B cells. Plasmablasts in the peripheral blood of ACPA + patients with RA showed significantly lower sialic acid surface content than that of plasmablasts from healthy control subjects (Fig. 6a) , which demonstrated diminished sialyltransferase activity in antibody-producing cells of patients with RA. We subsequently assessed the IgG-glycosylation pattern at Asn297 in IgG of serum collected from healthy human control subjects, asymptomatic ACPA + subjects who had not yet developed RA, and ACPA + patients with active RA. This analysis indicated less sialylation and galactosylation of IgG in ACPA + subjects than in healthy control subjects, with the IgG of patients with active RA showing the lowest content of sialic acid (Fig. 6b) . To measure the intrinsic inflammatory activity of the IgG from these groups of patients, we generated heataggregated ICs from the purified IgG, incubated them with human monocyte-derived dendritic cells from healthy donors and determined the IC-induced cytokine response by measuring IL-6, TNF and IL-8 in the cellular supernatant by ELISA. We observed that ICs from patients with active RA triggered greater production of TNF and IL-6 than did ICs from healthy control subjects or asymptomatic ACPA + subjects (Fig. 6c) . The treatment of IgG from asymptomatic ACPA + subjects with neuraminidase, in turn, resulted in an increase in its pro-inflammatory potential (Fig. 6d) , which indicated that the sialylation of IgG regulated the activity of IgG in ACPA + subjects. Analysis of the glycosylation status of IgG in a cohort of asymptomatic ACPA + subjects revealed that the subgroup that subsequently developed RA within 12 months had already displayed significant less sialylation and galactosylation of IgG and of ACPAs before the onset of arthritis than that of ACPA + subjects who remained healthy throughout the (Fig. 6e) . Together these data showed that the onset of RA was paralleled by diminished sialyltransferase activity in plasmablasts and less sialylation of RA-specific autoantibodies, which was a predictive factor for the progression to active RA.
DISCUSSION
Here we found that IL-23-activated T H 17 cells accumulated in germinal centers before the onset of arthritis, and there they downregulated expression of the sialyltransferase St6gal1 in newly developing plasmablasts and plasma cells in an IL-22-and IL-21-dependent manner. This T cell-driven reprogramming of the antibody-producing cells was paralleled by diminished glycosylation of autoantibodies, which unlocked their inflammatory potential and triggered the onset of arthritis. In contrast, IL-23 was dispensable during the following autoantibody-mediated phase of joint inflammation. These findings are in accordance with the fact that therapeutic targeting of IL-23 is effective during the prodromal phase of autoimmune arthritis but is ineffective after disease onset 22 . T H 17 cells can provide help to B cells, can promote IgG class switching and have been linked to germinal-center formation [23] [24] [25] [26] . However, our data indicated that IL-23-mediated activation of T H 17 cells, which promoted a pathogenic switch in this T cell subset, was not essential for their basic helper T cell ability, as IL-23-deficient mice displayed no alteration in germinal centers or the production of autoreactive IgG. Notably, the glycosylation and activity of total IgG was also unaffected by absence of IL-23, which demonstrates that this cytokine specifically affects the glycostructure of an IgG subset and is in line with data showing that ACPAs from patients with RA similarly exhibit a specific Fc-linked glycan profile that is distinct from that of total serum IgG 27 . Together with the observation that autoantibody glycosylation changes before the onset of RA 28 , these findings suggest that the T H 17 cell-mediated control of ST6gal1 expression in antibodyproducing cells resulted from an individual antigen-specific T cell-B cell interaction in the germinal center, before the onset of autoimmune arthritis. That, in turn, would indicate that the T H 17 cell-mediated control of IgG sialylation affects mainly antibodies that target antigens derived from an environment that had elicited an IL-23-driven T H 17 response. In accordance, T cell-dependent versus T cell-independent immunization protocols directed against model antigens such as OVA or TNP have been shown to result in distinct glycosylation patterns of the antigen-specific IgG response 29, 30 . Plasma cell development thus seems to follow a default program that usually involves high expression of St6gal1 and results in the production of neutralizing, highly sialylated and non-inflammatory antibodies. However, IL-23-dependent accumulation of follicular helper T cells that display a T H 17 signature and specific T H 17 cell-derived cytokines such as IL-22 seem to promote the suppression of St6gal1 in antibody-producing cells and can thereby promote a shift to a pro-inflammatory antibody repertoire. This pathway eventually unmasks a preexisting breach in humoral immunotolerance and can initiate the transition from a stage of asymptomatic autoimmunity to inflammatory autoimmune disease.
Although the autoantibodies of arthritic mice and IgG of patients with active RA displayed analogous alterations in sialylation, these changes were less pronounced in humans. However, our analysis of total IgG from individual patients might underestimate the actual decrease in the sialylation of functionally relevant RA autoantibodies in humans, as these are still incompletely defined. While our data did not reveal an effect of IL-23 on the galactosylation of IgG in arthritic mice, diminished galactosylation of IgG has been observed in patients with RA 28 , suggestive of species-specific differences and additional factors that control the glycosylation of IgG during human disease.
It is well established that asymptomatic autoimmunity and autoantibody formation precede, by several years, the symptomatic inflammatory phase in diseases such as RA 1 . However, so far it has been unclear how and when autoimmunity progresses to inflammatory disease. Our current work suggests that activation of the IL-23-T H 17 axis acts as a 'second hit' and promotes this transition to clinical disease. Although T H 17 cells have been indicated to be key participants in RA, targeting of IL-17 has only moderate potency in inducing clinical remission in human patients with active RA 31 . Our current data provide a molecular explanation for the puzzling results of such clinical trials and in turn suggest that during autoantibody-induced diseases like RA, targeting of the IL-23-T H 17 axis might be more efficient as a preventive treatment or as part of a therapeutic strategy during the maintenance of clinical remission after B cell depletion.
METHODS
Methods and any associated references are available in the online version of the paper. Cell preparation and flow cytometry. For flow cytometry, bone marrow, inguinal lymph nodes, spleens and paws were isolated. For single-cell isolation, paws were further digested for 1 h at 37 °C with collagenase D. Afterward, cells were stained for surface markers. If intracellular staining was done, cells were then fixed and permeabilized with the Foxp3 staining Kit (eBioscience) following the manufacturer's instructions. For intracellular cytokine analysis, cells were stimulated with phorbol 12-myristate 13 acetate and ionomycin (Sigma-Aldrich) for 6 h; monensin (BD-Bioscience) and brefeldin A (BioLegend) were added after 2 h. All flow cytometric analysis was performed on a Gallios Flow Cytometer (Beckman Coulter) and evaluated using the FlowJo or the Kaluza Flow Cytometry analysis software (Beckman Coulter).
Antibodies. The following fluorochrome-or biotin-conjugated anti-mouse antibodies and reagents were used (all at a dilution of 1:400 unless stated otherwise): anti-CD3 (17A2), anti-CD4 (GK1.5), anti-CD8a (53-6.7), anti-CD19 (6D5), anti-CD25 (PC61), anti-CD45R (RA3-6B2), anti-CD138 (281-2), anti-CD267 (8F10), anti-GR-1(RB6-8C5), anti-IL4(11B11), anti-IL-17A (1:200; TC11-18H10.1), anti-Foxp3 (MF-14), anti-IFN-γ (XMG1.2) and anti-PD-1 (MH5A) (all from BioLegend); anti-IL22Ra1 (clone 496514) (from R&D Systems); anti-RORγt (1:200; Q31-378) (from BD Bioscience); anti-St6gal1 (C) (18985; 1:100; from IBL); and normal rabbit IgG (isotype-matched control antibody Biotechnology (F0313)) (from Santa Cruz Biotechnology). OVA-specific plasma cells were stained intracellularly with intracellularly OVA-A488 ordered by Thermo-Fisher.
Human peripheral blood mononuclear cells (PBMCs) were stained with anti-CD19 (130-091-248; 1:20; Miltenyi Biotech), anti-CD27 (clone MT271 (RUO); 1:40; BD) and anti-CD38 (551400; 1:100; BD). Surface sialic acid was stained with SNA-fluorescein-isothiocyanate (VEC-FL-1301; 1:400) from Vector Laboratory.
For cytokine-blocking experiments and T H 17 differentiation, the following antibodies were used: anti-mouse CD3 (145-2C11), anti-mouse CD28 (37.51), anti-mouse GM-CSF (MP-22E9), anti-mouse IL-17A (TC11-18H10.1), antimouse/human IL21 (7H20-I19-M3) and anti-mouse IL22 (clone BL35175) (all from BioLegend).
B cell isolation. CD43 − splenic B cells were isolated from C57BL/6 mice by CD43 depletion using MACS technology (Miltenyi).
CD138 + CD19 + B220 − CD3 − GR1 − plasma cells were sorted out using the spleens of Il23a −/− and C57BL/6j mice before and during the induction of the CIA (Supplementary Fig. 2 ) using a MoFlo XDP cell sorter (Beckman Coulter).
PBMC isolation. PBMCs were separated from healthy donors by FicollDiatrizoate density-gradient centrifugation (Bio-Rad). After centrifugation, the PBMC-containing interphase was isolated and washed two times with 1 mM EDTA in PBS.
For SNA-lectin based flow cytometry, PBMCs were stained untreated or, as a negative control, were digested with neuraminidase (100 mU, 1 h at 37 °C), or sialic acid was oxidized using mild iodate treatment (2 mM in PBS).
Monocyte-derived dendritic cell (MoDC) differentiation. MoDCs were differentiated from monocytes isolated from PBMCs (via their ability to bind to plastic surfaces) and were cultivated in RPMI supplemented with 5% FCS (Biochrom), 1% penicillin-streptomycin (Gibco), 1% l-glutamine (Gibco) 1 mM HEPES and 1 mM sodium pyruvate (Sigma) in the presence of 800 U/ml GM-CSF (Peprotech) and 500 U/ml IL-4 (Peprotech). Cells were fed on day 3 and day 5. Experiments were performed on day 6 by co-incubation of MoDCs with heat-aggregated ICs after pre-conditioning of MoDCs with 0.5 ng/ml LPS.
T cell skewing and co cultures. Mouse splenic CD4 + T cells were isolated using EasySep (STEMCELL Technologies). T H 17 cells were differentiated with plate-bound 5 µg/ml anti-CD3 (100214; BioLegend) and IMDM medium (Lonza) supplemented with 3 µg/ml anti-CD28 (102111; BioLegend) and IL6 (10 ng/ml) and TGF-β (5 ng/ml, BioLegend), and for the pathogenic T H 17 cells, they were differentiated in the presence of IL6 (10 ng/ml, BioLegend) and IL-23 (20 ng/ml, R&D Systems). After 4 d of culture, T cells were collected and stimulated with PMA and ionomycin (Sigma-Aldrich) plus monensin (BD Biosciences) for intracellular cytokine staining.
For assays of T H 17 cell-mediated St6gal1 regulation in B cells, MACSenriched B cells were stimulated with LPS (5 µg/ml) and cultured together with T H 17 cells at a ratio of 2:1 in appropriate B cell medium. Blocking antibodies were purchased from BioLegend and used at a concentration of 2 mg/ml (anti-IL-17, TC11.18H1C1; anti-IL-21, 7H20I19-M3; anti-IL-22, Poly5164; anti-GM-CSF, MPA-22E9). After 72 h of culture, B cells were either sorted for RNA-isolation or analyzed via flow cytometry.
IgG isolation. Human IgG was obtained from healthy control subjects, asymptomatic ACPA + subjects that had not experienced arthritis yet and from ACPA + patients with active RA (clinical disease activity score, 28 3.2).
Mouse IgG was obtained from arthritic K/BxN, C57BL/6 (Charles River), DBA/1 or Il23a −/− mice on day 50 after immunization.
IgG was isolated by purification over a protein G column (GE Healthcare) according to the manufacturer's instructions. Collagen-specific IgG was isolated via chicken type II collagen bound on CNBr-activated Sepharose 4B (Sigma).
In vitro IgG modification. For desialylation, 1 mg of human or mouse IgG was incubated with 100 U or 200 U neuraminidase (NEB) for 24 h or 48 h, respectively, at 37 °C.
The efficiency of the enzymatic digestion was tested via lectin blot. Protein concentration was determined with NanoDrop 1000 (Thermo Scientific).
For galactosylation, 1 mg of mouse IgG was incubated with 0.8 mM UDPgalactose (Calbiochem) and 50 mU of β-1-4 galactosyl transferase (Sigma) in 50 mM MOPS, pH 7.2, with 20 mM MnCl 2 for 48 h at 37 °C. For subsequent sialylation, 1 mg of IgG was incubated with 0.5 mM CMP-sialic acid (Calbiochem) and 25 mU of α2-6 sialyl transferase (Sigma) in 50 mM MES, pH 6,0 with 20 mM MnCl 2 for 48 h at 37 °C. The reactions were confirmed with a lectin blot.
Fc-glycosylation analysis of IgG isolated from Il23a −/− and wild-type mice. For the analysis of Fc-glycans, the IgG eluates were dried in a vacuum centrifuge and subjected to tryptic digestion by adding 200 ng trypsin (sequencing grade, Promega) in 40 µl ammonium bicarbonate buffer followed by overnight incubation at 37 °C. Digested IgG from Il23a −/− and wild-type mice were separated and analyzed on an Ultimate 3000 UPLC system (Dionex Corporation, USA) coupled to a maXis HD Ultra-High Resolution Q-TOF mass spectrometer (Bruker Daltonics, Germany) as described previously with minor modifications 36, 37 . Following extraction of tryptic glycopeptides by a C18 solid-phase extraction-trap column (Dionex Acclaim PepMap100), separation was achieved on an Ascentis Express C18 nano-liquid chromatography (LC) column (Supelco, USA) conditioned at 900 nl/min with 0.1% TFA (mobile phase A) after which the following gradient of mobile phase A and 95% acetonitrile (mobile phase B) was applied: 0 min 3% B, 2 min 6% B, 4.5 min 18% B, 5 min 30% B, 7 min 30% B, 8 min 0% B and 11 min 0% B. The UPLC was interfaced to the mass spectrometer with a sheath-flow ESI sprayer. Mass spectra were recorded from m/z 600 to 2,000 with two averages at a frequency of 0.5 Hz. Quadrupole ion energy and collision energy of the mass spectrometer were set at 2 eV and 4 eV, respectively. The total analysis time per sample was 13 min. Quality of mass spectra was evaluated based on intensities of total IgG1 glycoforms. Data processing and calculations of the level of galactosylation, sialylation, and fucosylation residues of IgG1and IgG2 were performed as described earlier 38 .
BMDC stimulation and assessment of IC activity. For measuring the intrinsic inflammatory capacity of mouse total and collagen type II specific IgG antibodies, bone-marrow cells were isolated from femora and tibiae of 6-to 8-week-old mice. Cell populations depleted of erythrocytes were seeded in R10 medium at a concentration of 2 × 10 6 cells per 10-cm dish (Falcon, no. 1029, bacterial quality) R10 culture medium is composed of RPMI 1640 (Lonza)
